APO Research
Talk to an analyst

APO RESEARCH · REPORT

Meningococcal Vaccine

Meningococcal vaccine refers to any of the vaccines used to prevent infection by Neisseria meningitides. The vaccines are between 85 and 100% effective for at least two years. They result in a decrease in meningitis and sepsis among populations where they are widely used. They are given either by injection into a muscle or just under the skin.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Meningococcal vaccine refers to any of the vaccines used to prevent infection by Neisseria meningitides. The vaccines are between 85 and 100% effective for at least two years. They result in a decrease in meningitis and sepsis among populations where they are widely used. They are given either by injection into a muscle or just under the skin.

Selected research

Industry Growth & Trends

Global Meningococcal Vaccine Industry Growth and Trends Forecast to 2032

20 December 2025107 pages

Choose your research edition.

Industry ResearchMeningococcal Vaccine Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Meningococcal Vaccine Industry Growth and Trends Forecast to 2032107 pages · $3,450 USDMarket StructureGlobal Meningococcal Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Meningococcal Vaccine Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Meningococcal Vaccine Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

Meningococcal vaccine refers to any of the vaccines used to prevent infection by Neisseria meningitides. The vaccines are between 85 and 100% effective for at least two years. They result in a decrease in meningitis and sepsis among populations where they are widely used. They are given either by injection into a muscle or just under the skin.

Global Meningococcal Vaccine key players include GSK, SANOFI PASTEUR S.A, Norvatis, Crucell, Medimmune, etc. Global top five players hold a share about 80%.

Europe is the largest market, with a share about 45%, followed by North America and China, having a total share about 40 percent.

Read the full market overview

In terms of product, Polysaccharide Meningtitis AC is the largest segment, with a share about 95%. And in terms of application, the largest application is 6 Months-15Year, followed by over 3 Year, over 2 Year, over 3 Months.

Report Scope

This report provides a structured, data-driven view of the global Meningococcal Vaccine market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Meningococcal Vaccine market size, estimates, and forecasts are presented in terms of sales volume (10K Pcs) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Meningococcal Vaccine market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Meningococcal Vaccine.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Meningococcal Vaccine market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Meningococcal Vaccine Market by Company

Novartis

GSK

Merck

CSL

Baxter

JN International Medical Corporation

Serum Institute of India

Bio-Med

China National Biotec Group

Hualan Bio

Walvax

Zhifei

Meningococcal Vaccine Segment by Type

Meningtits A

Polysaccharide Meningtitis AC

Meningitis ACYW

Meningococcal Vaccine Segment by Application

6 Months-15Year

over 3 Year

over 2 Year

over 3 Months

Meningococcal Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Meningococcal Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Meningococcal Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Meningococcal Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Meningococcal Vaccine manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Meningococcal Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Meningtits A Table 2. Major Company of Polysaccharide Meningtitis AC Table 3. Major Company of Meningitis ACYW Table 4. Global Meningococcal Vaccine Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Meningococcal Vaccine Sales by Type (2021-2026) & (10K Pcs) Table 6. Global Meningococcal Vaccine Sales Market Share in Volume by Type (2021-2026) Table 7. Global Meningococcal Vaccine Sales by Type (2021-2026) & (US$ Million) Table 8. Global Meningococcal Vaccine Sales Market Share in Value by Type (2021-2026) Table 9. Global Meningococcal Vaccine Price by Type (2021-2026) & (USD/Pcs) Table 10. Global Meningococcal Vaccine Sales by Type (2027-2032) & (10K Pcs) Table 11. Global Meningococcal Vaccine Sales Market Share in Volume by Type (2027-2032) Table 12. Global Meningococcal Vaccine Sales by Type (2027-2032) & (US$ Million) Table 13. Global Meningococcal Vaccine Sales Market Share in Value by Type (2027-2032) Table 14. Global Meningococcal Vaccine Price by Type (2027-2032) & (USD/Pcs) Table 15. North America Meningococcal Vaccine Sales by Type (2021-2026) & (10K Pcs) Table 16. North America Meningococcal Vaccine Sales by Type (2021-2026) & (US$ Million) Table 17. Europe Meningococcal Vaccine Sales by Type (2021-2026) & (10K Pcs) Table 18. Europe Meningococcal Vaccine Sales by Type (2021-2026) & (US$ Million) Table 19. Asia-Pacific Meningococcal Vaccine Sales by Type (2021-2026) & (10K Pcs) Table 20. Asia-Pacific Meningococcal Vaccine Sales by Type (2021-2026) & (US$ Million) Table 21. Latin America Meningococcal Vaccine Sales by Type (2021-2026) & (10K Pcs) Table 22. Latin America Meningococcal Vaccine Sales by Type (2021-2026) & (US$ Million) Table 23. Middle East and Africa Meningococcal Vaccine Sales by Type (2021-2026) & (10K Pcs) Table 24. Middle East and Africa Meningococcal Vaccine Sales by Type (2021-2026) & (US$ Million) Table 25. Meningococcal Vaccine Industry Trends Table 26. Meningococcal Vaccine Industry Drivers Table 27. Meningococcal Vaccine Industry Opportunities and Challenges Table 28. Meningococcal Vaccine Industry Restraints Table 29. Global Meningococcal Vaccine Sales Revenue by Company (US$ Million) & (2021-2026) Table 30. Global Meningococcal Vaccine Revenue Market Share by Company (2021-2026) Table 31. Global Meningococcal Vaccine Sales by Company (2021-2026) & (10K Pcs) Table 32. Global Meningococcal Vaccine Sales Share by Company (2021-2026) Table 33. Global Meningococcal Vaccine Market Price by Company (2021-2026) & (USD/Pcs) Table 34. Global Meningococcal Vaccine Industry Company Ranking, 2024 VS 2025 VS 2026 Table 35. Global Meningococcal Vaccine Major Company Production Sites and Headquarters Table 36. Global Meningococcal Vaccine Company, Product Type & Application Table 37. Global Meningococcal Vaccine Company Establishment Date Table 38. Global Company Market Concentration Ratio (CR5 and HHI) Table 39. Global Meningococcal Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 40. Global Meningococcal Vaccine Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 41. Global Meningococcal Vaccine Sales by Region (2021-2026) & (10K Pcs) Table 42. Global Meningococcal Vaccine Sales Market Share in Volume by Region (2021-2026) Table 43. Global Meningococcal Vaccine Sales by Region (2021-2026) & (US$ Million) Table 44. Global Meningococcal Vaccine Sales Market Share in Value by Region (2021-2026) Table 45. Global Meningococcal Vaccine Sales (10K Pcs), Value (US$ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 46. Global Meningococcal Vaccine Sales by Region (2027-2032) & (10K Pcs) Table 47. Global Meningococcal Vaccine Sales Market Share in Volume by Region (2027-2032) Table 48. Global Meningococcal Vaccine Sales by Region (2027-2032) & (US$ Million) Table 49. Global Meningococcal Vaccine Sales Market Share in Value by Region (2027-2032) Table 50. Global Meningococcal Vaccine Sales (10K Pcs), Value (US$ Million), Price (USD/Pcs) and Gross Margin (2027-2032) Table 51. Global Meningococcal Vaccine Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 52. Global Meningococcal Vaccine Sales by Application (2021-2026) & (10K Pcs) Table 53. Global Meningococcal Vaccine Sales Market Share in Volume by Application (2021-2026) Table 54. Global Meningococcal Vaccine Sales by Application (2021-2026) & (US$ Million) Table 55. Global Meningococcal Vaccine Sales Market Share in Value by Application (2021-2026) Table 56. Global Meningococcal Vaccine Price by Application (2021-2026) & (USD/Pcs) Table 57. Global Meningococcal Vaccine Sales by Application (2027-2032) & (10K Pcs) Table 58. Global Meningococcal Vaccine Sales Market Share in Volume by Application (2027-2032) Table 59. Global Meningococcal Vaccine Sales by Application (2027-2032) & (US$ Million) Table 60. Global Meningococcal Vaccine Sales Market Share in Value by Application (2027-2032) Table 61. Global Meningococcal Vaccine Price by Application (2027-2032) & (USD/Pcs) Table 62. North America Meningococcal Vaccine Sales by Application (2021-2026) & (10K Pcs) Table 63. North America Meningococcal Vaccine Sales by Application (2021-2026) & (US$ Million) Table 64. Europe Meningococcal Vaccine Sales by Application (2021-2026) & (10K Pcs) Table 65. Europe Meningococcal Vaccine Sales by Application (2021-2026) & (US$ Million) Table 66. Asia-Pacific Meningococcal Vaccine Sales by Application (2021-2026) & (10K Pcs) Table 67. Asia-Pacific Meningococcal Vaccine Sales by Application (2021-2026) & (US$ Million) Table 68. Latin America Meningococcal Vaccine Sales by Application (2021-2026) & (10K Pcs) Table 69. Latin America Meningococcal Vaccine Sales by Application (2021-2026) & (US$ Million) Table 70. Middle East and Africa Meningococcal Vaccine Sales by Application (2021-2026) & (10K Pcs) Table 71. Middle East and Africa Meningococcal Vaccine Sales by Application (2021-2026) & (US$ Million) Table 72. Novartis Company Information Table 73. Novartis Business Overview Table 74. Novartis Meningococcal Vaccine Sales (10K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 75. Novartis Meningococcal Vaccine Product Portfolio Table 76. Novartis Recent Development Table 77. GSK Company Information Table 78. GSK Business Overview Table 79. GSK Meningococcal Vaccine Sales (10K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 80. GSK Meningococcal Vaccine Product Portfolio Table 81. GSK Recent Development Table 82. Merck Company Information Table 83. Merck Business Overview Table 84. Merck Meningococcal Vaccine Sales (10K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 85. Merck Meningococcal Vaccine Product Portfolio Table 86. Merck Recent Development Table 87. CSL Company Information Table 88. CSL Business Overview Table 89. CSL Meningococcal Vaccine Sales (10K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 90. CSL Meningococcal Vaccine Product Portfolio Table 91. CSL Recent Development Table 92. Baxter Company Information Table 93. Baxter Business Overview Table 94. Baxter Meningococcal Vaccine Sales (10K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 95. Baxter Meningococcal Vaccine Product Portfolio Table 96. Baxter Recent Development Table 97. JN International Medical Corporation Company Information Table 98. JN International Medical Corporation Business Overview Table 99. JN International Medical Corporation Meningococcal Vaccine Sales (10K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 100. JN International Medical Corporation Meningococcal Vaccine Product Portfolio Table 101. JN International Medical Corporation Recent Development Table 102. Serum Institute of India Company Information Table 103. Serum Institute of India Business Overview Table 104. Serum Institute of India Meningococcal Vaccine Sales (10K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 105. Serum Institute of India Meningococcal Vaccine Product Portfolio Table 106. Serum Institute of India Recent Development Table 107. Bio-Med Company Information Table 108. Bio-Med Business Overview Table 109. Bio-Med Meningococcal Vaccine Sales (10K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 110. Bio-Med Meningococcal Vaccine Product Portfolio Table 111. Bio-Med Recent Development Table 112. China National Biotec Group Company Information Table 113. China National Biotec Group Business Overview Table 114. China National Biotec Group Meningococcal Vaccine Sales (10K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 115. China National Biotec Group Meningococcal Vaccine Product Portfolio Table 116. China National Biotec Group Recent Development Table 117. Hualan Bio Company Information Table 118. Hualan Bio Business Overview Table 119. Hualan Bio Meningococcal Vaccine Sales (10K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 120. Hualan Bio Meningococcal Vaccine Product Portfolio Table 121. Hualan Bio Recent Development Table 122. Walvax Company Information Table 123. Walvax Business Overview Table 124. Walvax Meningococcal Vaccine Sales (10K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 125. Walvax Meningococcal Vaccine Product Portfolio Table 126. Walvax Recent Development Table 127. Zhifei Company Information Table 128. Zhifei Business Overview Table 129. Zhifei Meningococcal Vaccine Sales (10K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2021-2026) Table 130. Zhifei Meningococcal Vaccine Product Portfolio Table 131. Zhifei Recent Development Table 132. North America Meningococcal Vaccine Market Size Growth Rate (CAGR) by Country (10K Pcs): 2021 VS 2025 VS 2032 Table 133. North America Meningococcal Vaccine Sales by Country (2021-2026) & (10K Pcs) Table 134. North America Meningococcal Vaccine Sales Market Share by Country (2021-2026) Table 135. North America Meningococcal Vaccine Sales Forecast by Country (2027-2032) & (10K Pcs) Table 136. North America Meningococcal Vaccine Sales Market Share Forecast by Country (2027-2032) Table 137. North America Meningococcal Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 138. North America Meningococcal Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 139. North America Meningococcal Vaccine Market Share by Country (2021-2026) Table 140. North America Meningococcal Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 141. North America Meningococcal Vaccine Market Share Forecast by Country (2027-2032) Table 142. Europe Meningococcal Vaccine Market Size Growth Rate (CAGR) by Country (10K Pcs): 2021 VS 2025 VS 2032 Table 143. Europe Meningococcal Vaccine Sales by Country (2021-2026) & (10K Pcs) Table 144. Europe Meningococcal Vaccine Sales Market Share by Country (2021-2026) Table 145. Europe Meningococcal Vaccine Sales Forecast by Country (2027-2032) & (10K Pcs) Table 146. Europe Meningococcal Vaccine Sales Market Share Forecast by Country (2027-2032) Table 147. Europe Meningococcal Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 148. Europe Meningococcal Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 149. Europe Meningococcal Vaccine Market Share by Country (2021-2026) Table 150. Europe Meningococcal Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 151. Europe Meningococcal Vaccine Market Share Forecast by Country (2027-2032) Table 152. Asia-Pacific Meningococcal Vaccine Market Size Growth Rate (CAGR) by Country (10K Pcs): 2021 VS 2025 VS 2032 Table 153. Asia-Pacific Meningococcal Vaccine Sales by Country (2021-2026) & (10K Pcs) Table 154. Asia-Pacific Meningococcal Vaccine Sales Market Share by Country (2021-2026) Table 155. Asia-Pacific Meningococcal Vaccine Sales Forecast by Country (2027-2032) & (10K Pcs) Table 156. Asia-Pacific Meningococcal Vaccine Sales Market Share Forecast by Country (2027-2032) Table 157. Asia-Pacific Meningococcal Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 158. Asia-Pacific Meningococcal Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 159. Asia-Pacific Meningococcal Vaccine Market Share by Country (2021-2026) Table 160. Asia-Pacific Meningococcal Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 161. Asia-Pacific Meningococcal Vaccine Market Share Forecast by Country (2027-2032) Table 162. Latin America Meningococcal Vaccine Market Size Growth Rate (CAGR) by Country (10K Pcs): 2021 VS 2025 VS 2032 Table 163. Latin America Meningococcal Vaccine Sales by Country (2021-2026) & (10K Pcs) Table 164. Latin America Meningococcal Vaccine Sales Market Share by Country (2021-2026) Table 165. Latin America Meningococcal Vaccine Sales Forecast by Country (2027-2032) & (10K Pcs) Table 166. Latin America Meningococcal Vaccine Sales Market Share Forecast by Country (2027-2032) Table 167. Latin America Meningococcal Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 168. Latin America Meningococcal Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 169. Latin America Meningococcal Vaccine Market Share by Country (2021-2026) Table 170. Latin America Meningococcal Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 171. Latin America Meningococcal Vaccine Market Share Forecast by Country (2027-2032) Table 172. Middle East and Africa Meningococcal Vaccine Market Size Growth Rate (CAGR) by Country (10K Pcs): 2021 VS 2025 VS 2032 Table 173. Middle East and Africa Meningococcal Vaccine Sales by Country (2021-2026) & (10K Pcs) Table 174. Middle East and Africa Meningococcal Vaccine Sales Market Share by Country (2021-2026) Table 175. Middle East and Africa Meningococcal Vaccine Sales Forecast by Country (2027-2032) & (10K Pcs) Table 176. Middle East and Africa Meningococcal Vaccine Sales Market Share Forecast by Country (2027-2032) Table 177. Middle East and Africa Meningococcal Vaccine Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 178. Middle East and Africa Meningococcal Vaccine Market Size by Country (2021-2026) & (US$ Million) Table 179. Middle East and Africa Meningococcal Vaccine Market Share by Country (2021-2026) Table 180. Middle East and Africa Meningococcal Vaccine Market Size Forecast by Country (2027-2032) & (US$ Million) Table 181. Middle East and Africa Meningococcal Vaccine Market Share Forecast by Country (2027-2032) Table 182. Key Raw Materials Table 183. Raw Materials Key Suppliers Table 184. Meningococcal Vaccine Distributors List Table 185. Meningococcal Vaccine Customers List Table 186. Research Programs/Design for This Report Table 187. Authors List of This Report Table 188. Secondary Sources Table 189. Primary Sources List of Figures Figure 1. Meningococcal Vaccine Image Figure 2. Global Meningococcal Vaccine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Meningococcal Vaccine Market Size (2021-2032) & (US$ Million) Figure 4. Global Meningococcal Vaccine Sales (2021-2032) & (10K Pcs) Figure 5. Meningtits A Image Figure 6. Global Meningtits A Sales YoY Growth (2021-2032) & (10K Pcs) Figure 7. Polysaccharide Meningtitis AC Image Figure 8. Global Polysaccharide Meningtitis AC Sales YoY Growth (2021-2032) & (10K Pcs) Figure 9. Meningitis ACYW Image Figure 10. Global Meningitis ACYW Sales YoY Growth (2021-2032) & (10K Pcs) Figure 11. Global Meningococcal Vaccine Market Size Overview by Type (2021-2032) & (US$ Million) Figure 12. Global Meningococcal Vaccine Market Share by Type 2025 VS 2032 Figure 13. North America Meningococcal Vaccine Sales Market Share in Volume by Type in 2025 Figure 14. North America Meningococcal Vaccine Sales Market Share in Value by Type in 2025 Figure 15. Europe Meningococcal Vaccine Sales Market Share in Volume by Type in 2025 Figure 16. Europe Meningococcal Vaccine Sales Market Share in Value by Type in 2025 Figure 17. Asia-Pacific Meningococcal Vaccine Sales Market Share in Volume by Type in 2025 Figure 18. Asia-Pacific Meningococcal Vaccine Sales Market Share in Value by Type in 2025 Figure 19. Latin America Meningococcal Vaccine Sales Market Share in Volume by Type in 2025 Figure 20. Latin America Meningococcal Vaccine Sales Market Share in Value by Type in 2025 Figure 21. Middle East and Africa Meningococcal Vaccine Sales Market Share in Volume by Type in 2025 Figure 22. Middle East and Africa Meningococcal Vaccine Sales Market Share in Value by Type in 2025 Figure 23. Global Top 5 and 10 Meningococcal Vaccine Players Market Share by Revenue in 2025 Figure 24. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 25. 6 Months-15Year Image Figure 26. Global 6 Months-15Year Sales YoY Growth (2021-2032) & (10K Pcs) Figure 27. over 3 Year Image Figure 28. Global over 3 Year Sales YoY Growth (2021-2032) & (10K Pcs) Figure 29. over 2 Year Image Figure 30. Global over 2 Year Sales YoY Growth (2021-2032) & (10K Pcs) Figure 31. over 3 Months Image Figure 32. Global over 3 Months Sales YoY Growth (2021-2032) & (10K Pcs) Figure 33. Global Meningococcal Vaccine Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global Meningococcal Vaccine Market Share by Application 2025 VS 2032 Figure 35. North America Meningococcal Vaccine Sales Market Share in Volume by Application in 2025 Figure 36. North America Meningococcal Vaccine Sales Market Share in Value by Application in 2025 Figure 37. Europe Meningococcal Vaccine Sales Market Share in Volume by Application in 2025 Figure 38. Europe Meningococcal Vaccine Sales Market Share in Value by Application in 2025 Figure 39. Asia-Pacific Meningococcal Vaccine Sales Market Share in Volume by Application in 2025 Figure 40. Asia-Pacific Meningococcal Vaccine Sales Market Share in Value by Application in 2025 Figure 41. Latin America Meningococcal Vaccine Sales Market Share in Volume by Application in 2025 Figure 42. Latin America Meningococcal Vaccine Sales Market Share in Value by Application in 2025 Figure 43. Middle East and Africa Meningococcal Vaccine Sales Market Share in Volume by Application in 2025 Figure 44. Middle East and Africa Meningococcal Vaccine Sales Market Share in Value by Application in 2025 Figure 45. North America Meningococcal Vaccine Sales by Country: 2021 VS 2025 VS 2032 (10K Pcs) Figure 46. North America Meningococcal Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. North America Meningococcal Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. North America Meningococcal Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Meningococcal Vaccine Sales by Country: 2021 VS 2025 VS 2032 (10K Pcs) Figure 50. Europe Meningococcal Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Meningococcal Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Europe Meningococcal Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Meningococcal Vaccine Sales by Country: 2021 VS 2025 VS 2032 (10K Pcs) Figure 54. Asia-Pacific Meningococcal Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Meningococcal Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Asia-Pacific Meningococcal Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Meningococcal Vaccine Sales by Country: 2021 VS 2025 VS 2032 (10K Pcs) Figure 58. Latin America Meningococcal Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Meningococcal Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Latin America Meningococcal Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Meningococcal Vaccine Sales by Country: 2021 VS 2025 VS 2032 (10K Pcs) Figure 62. Middle East and Africa Meningococcal Vaccine Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Meningococcal Vaccine Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Middle East and Africa Meningococcal Vaccine Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Meningococcal Vaccine Value Chain Figure 66. Key Raw Materials Price Figure 67. Manufacturing Cost Structure Figure 68. Meningococcal Vaccine Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Meningtits A
  • Polysaccharide Meningtitis AC
  • Meningitis ACYW
Applications
  • 6 Months-15Year
  • over 3 Year
  • over 2 Year
  • over 3 Months
Companies covered
  • Novartis
  • GSK
  • Merck
  • CSL
  • Baxter
  • JN International Medical Corporation
  • Serum Institute of India
  • Bio-Med
  • China National Biotec Group
  • Hualan Bio
  • Walvax
  • Zhifei

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Meningococcal Vaccine Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Meningococcal Vaccine Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Meningococcal Vaccine Market by Type
  6. 1.3.1 Meningtits A
  7. 1.3.2 Polysaccharide Meningtitis AC
  8. 1.3.3 Meningitis ACYW
  9. 1.4 Global Meningococcal Vaccine Market Size by Type
  10. 1.4.1 Global Meningococcal Vaccine Market Size Overview by Type (2021-2032)
  11. 1.4.2 Global Meningococcal Vaccine Historic Market Size Review by Type (2021-2026)
  12. 1.4.3 Global Meningococcal Vaccine Forecasted Market Size by Type (2027-2032)
  13. 1.5 Key Regions Market Size by Type
  14. 1.5.1 North America Meningococcal Vaccine Sales Breakdown by Type (2021-2026)
  15. 1.5.2 Europe Meningococcal Vaccine Sales Breakdown by Type (2021-2026)
  16. 1.5.3 Asia-Pacific Meningococcal Vaccine Sales Breakdown by Type (2021-2026)
  17. 1.5.4 South America Meningococcal Vaccine Sales Breakdown by Type (2021-2026)
  18. 1.5.5 Middle East and Africa Meningococcal Vaccine Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Meningococcal Vaccine Industry Trends
  2. 2.2 Meningococcal Vaccine Industry Drivers
  3. 2.3 Meningococcal Vaccine Industry Opportunities and Challenges
  4. 2.4 Meningococcal Vaccine Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Meningococcal Vaccine Revenue (2021-2026)
  2. 3.2 Global Top Players by Meningococcal Vaccine Sales (2021-2026)
  3. 3.3 Global Top Players by Meningococcal Vaccine Price (2021-2026)
  4. 3.4 Global Meningococcal Vaccine Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Meningococcal Vaccine Major Company Production Sites & Headquarters
  6. 3.6 Global Meningococcal Vaccine Company, Product Type & Application
  7. 3.7 Global Meningococcal Vaccine Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Meningococcal Vaccine Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Meningococcal Vaccine Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Meningococcal Vaccine Tier 1, Tier 2, and Tier 3
4 Meningococcal Vaccine Regional Status and Outlook
  1. 4.1 Global Meningococcal Vaccine Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Meningococcal Vaccine Historic Market Size by Region
  3. 4.2.1 Global Meningococcal Vaccine Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Meningococcal Vaccine Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Meningococcal Vaccine Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Meningococcal Vaccine Forecasted Market Size by Region
  7. 4.3.1 Global Meningococcal Vaccine Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Meningococcal Vaccine Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Meningococcal Vaccine Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Meningococcal Vaccine by Application
  1. 5.1 Meningococcal Vaccine Market by Application
  2. 5.1.1 6 Months-15Year
  3. 5.1.2 over 3 Year
  4. 5.1.3 over 2 Year
  5. 5.1.4 over 3 Months
  6. 5.2 Global Meningococcal Vaccine Market Size by Application
  7. 5.2.1 Global Meningococcal Vaccine Market Size Overview by Application (2021-2032)
  8. 5.2.2 Global Meningococcal Vaccine Historic Market Size Review by Application (2021-2026)
  9. 5.2.3 Global Meningococcal Vaccine Forecasted Market Size by Application (2027-2032)
  10. 5.3 Key Regions Market Size by Application
  11. 5.3.1 North America Meningococcal Vaccine Sales Breakdown by Application (2021-2026)
  12. 5.3.2 Europe Meningococcal Vaccine Sales Breakdown by Application (2021-2026)
  13. 5.3.3 Asia-Pacific Meningococcal Vaccine Sales Breakdown by Application (2021-2026)
  14. 5.3.4 South America Meningococcal Vaccine Sales Breakdown by Application (2021-2026)
  15. 5.3.5 Middle East and Africa Meningococcal Vaccine Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Novartis
  2. 6.1.1 Novartis Company Information
  3. 6.1.2 Novartis Business Overview
  4. 6.1.3 Novartis Meningococcal Vaccine Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Novartis Meningococcal Vaccine Product Portfolio
  6. 6.1.5 Novartis Recent Developments
  7. 6.2 GSK
  8. 6.2.1 GSK Company Information
  9. 6.2.2 GSK Business Overview
  10. 6.2.3 GSK Meningococcal Vaccine Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 GSK Meningococcal Vaccine Product Portfolio
  12. 6.2.5 GSK Recent Developments
  13. 6.3 Merck
  14. 6.3.1 Merck Company Information
  15. 6.3.2 Merck Business Overview
  16. 6.3.3 Merck Meningococcal Vaccine Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Merck Meningococcal Vaccine Product Portfolio
  18. 6.3.5 Merck Recent Developments
  19. 6.4 CSL
  20. 6.4.1 CSL Company Information
  21. 6.4.2 CSL Business Overview
  22. 6.4.3 CSL Meningococcal Vaccine Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 CSL Meningococcal Vaccine Product Portfolio
  24. 6.4.5 CSL Recent Developments
  25. 6.5 Baxter
  26. 6.5.1 Baxter Company Information
  27. 6.5.2 Baxter Business Overview
  28. 6.5.3 Baxter Meningococcal Vaccine Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Baxter Meningococcal Vaccine Product Portfolio
  30. 6.5.5 Baxter Recent Developments
  31. 6.6 JN International Medical Corporation
  32. 6.6.1 JN International Medical Corporation Company Information
  33. 6.6.2 JN International Medical Corporation Business Overview
  34. 6.6.3 JN International Medical Corporation Meningococcal Vaccine Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 JN International Medical Corporation Meningococcal Vaccine Product Portfolio
  36. 6.6.5 JN International Medical Corporation Recent Developments
  37. 6.7 Serum Institute of India
  38. 6.7.1 Serum Institute of India Company Information
  39. 6.7.2 Serum Institute of India Business Overview
  40. 6.7.3 Serum Institute of India Meningococcal Vaccine Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Serum Institute of India Meningococcal Vaccine Product Portfolio
  42. 6.7.5 Serum Institute of India Recent Developments
  43. 6.8 Bio-Med
  44. 6.8.1 Bio-Med Company Information
  45. 6.8.2 Bio-Med Business Overview
  46. 6.8.3 Bio-Med Meningococcal Vaccine Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Bio-Med Meningococcal Vaccine Product Portfolio
  48. 6.8.5 Bio-Med Recent Developments
  49. 6.9 China National Biotec Group
  50. 6.9.1 China National Biotec Group Company Information
  51. 6.9.2 China National Biotec Group Business Overview
  52. 6.9.3 China National Biotec Group Meningococcal Vaccine Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 China National Biotec Group Meningococcal Vaccine Product Portfolio
  54. 6.9.5 China National Biotec Group Recent Developments
  55. 6.10 Hualan Bio
  56. 6.10.1 Hualan Bio Company Information
  57. 6.10.2 Hualan Bio Business Overview
  58. 6.10.3 Hualan Bio Meningococcal Vaccine Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Hualan Bio Meningococcal Vaccine Product Portfolio
  60. 6.10.5 Hualan Bio Recent Developments
  61. 6.11 Walvax
  62. 6.11.1 Walvax Company Information
  63. 6.11.2 Walvax Business Overview
  64. 6.11.3 Walvax Meningococcal Vaccine Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Walvax Meningococcal Vaccine Product Portfolio
  66. 6.11.5 Walvax Recent Developments
  67. 6.12 Zhifei
  68. 6.12.1 Zhifei Company Information
  69. 6.12.2 Zhifei Business Overview
  70. 6.12.3 Zhifei Meningococcal Vaccine Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Zhifei Meningococcal Vaccine Product Portfolio
  72. 6.12.5 Zhifei Recent Developments
7 North America by Country
  1. 7.1 North America Meningococcal Vaccine Sales by Country
  2. 7.1.1 North America Meningococcal Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Meningococcal Vaccine Sales by Country (2021-2026)
  4. 7.1.3 North America Meningococcal Vaccine Sales Forecast by Country (2027-2032)
  5. 7.2 North America Meningococcal Vaccine Market Size by Country
  6. 7.2.1 North America Meningococcal Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Meningococcal Vaccine Market Size by Country (2021-2026)
  8. 7.2.3 North America Meningococcal Vaccine Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Meningococcal Vaccine Sales by Country
  2. 8.1.1 Europe Meningococcal Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Meningococcal Vaccine Sales by Country (2021-2026)
  4. 8.1.3 Europe Meningococcal Vaccine Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Meningococcal Vaccine Market Size by Country
  6. 8.2.1 Europe Meningococcal Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Meningococcal Vaccine Market Size by Country (2021-2026)
  8. 8.2.3 Europe Meningococcal Vaccine Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Meningococcal Vaccine Sales by Country
  2. 9.1.1 Asia-Pacific Meningococcal Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Meningococcal Vaccine Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Meningococcal Vaccine Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Meningococcal Vaccine Market Size by Country
  6. 9.2.1 Asia-Pacific Meningococcal Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Meningococcal Vaccine Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Meningococcal Vaccine Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Meningococcal Vaccine Sales by Country
  2. 10.1.1 South America Meningococcal Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Meningococcal Vaccine Sales by Country (2021-2026)
  4. 10.1.3 South America Meningococcal Vaccine Sales Forecast by Country (2027-2032)
  5. 10.2 South America Meningococcal Vaccine Market Size by Country
  6. 10.2.1 South America Meningococcal Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Meningococcal Vaccine Market Size by Country (2021-2026)
  8. 10.2.3 South America Meningococcal Vaccine Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Meningococcal Vaccine Sales by Country
  2. 11.1.1 Middle East and Africa Meningococcal Vaccine Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Meningococcal Vaccine Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Meningococcal Vaccine Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Meningococcal Vaccine Market Size by Country
  6. 11.2.1 Middle East and Africa Meningococcal Vaccine Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Meningococcal Vaccine Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Meningococcal Vaccine Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Meningococcal Vaccine Value Chain Analysis
  2. 12.1.1 Meningococcal Vaccine Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Meningococcal Vaccine Production Mode & Process
  7. 12.2 Meningococcal Vaccine Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Meningococcal Vaccine Distributors
  10. 12.2.3 Meningococcal Vaccine Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst